729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors

• Kyungwha Lee,
• Jeeyun Lee,
• Mahesh Seetharam,
• Jae Lyun Lee,
• Jung-Yun Lee,
• Byoung Chul Cho,
• Myoung Ho Jang,
• Yujie Zhao,
• Nari Yun,
• Alex A Adjei,
• Chong Woo Park,
• Jian L Campian,
• Wen Wee Ma,
• Dongwoo Chae,
• Woosun Lee,
• Wooyul Lee,
• Sosun Park,
• Bochan Seo

Affiliations

Kyungwha Lee

Aff1 grid.31501.360000000404705905Wide River Institute of ImmunologySeoul National University Republic of Korea

Jeeyun Lee

Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Republic of Korea

Mahesh Seetharam

3Mayo Clinic, Rochester, MN, USA

Jae Lyun Lee

Aff7 grid.267370.70000 0004 0533 4667Asan Medical Center and University of Ulsan College of Medicine Seoul South Korea

Jung-Yun Lee

3Seoul National University Bundang Hospital, Department of Obstetrics and Gynecology, Seongnam, Korea, Republic of

Byoung Chul Cho

9Yonsei Cancer Center, Seoul, Korea, Republic of

Myoung Ho Jang

9GI Innovation, Inc, Seoul, Republic of Korea

Yujie Zhao

1 Department of Epidemiology and Biostatistics, Institute of Basic Medical Science, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, China

Nari Yun

4GI Innovation, Inc, Seoul, Kosovo, Republic of

Alex A Adjei

Mayo Clinic, Rochester, Minnesota, USA

Chong Woo Park

GI Innovation Inc., Seoul, Songpa-gu, Republic of Korea

Jian L Campian

5Mayo Clinic, Rochester, MN, USA

Wen Wee Ma

8Cleveland Clinic, Cleveland, OH, USA

Dongwoo Chae

4Yonsei University, Seoul, Republic of Korea

Woosun Lee

9GI Innovation, Inc, Seoul, Republic of Korea

Wooyul Lee

9GI Innovation, Inc, Seoul, Republic of Korea

Sosun Park

9GI Innovation, Inc, Seoul, Republic of Korea

Bochan Seo

9GI Innovation, Inc, Seoul, Republic of Korea